Contact: Jade Boyd
Caption: The first preclinical study of the anti-cancer technology "quadrapeutics" found it to be 17 times more efficient than conventional chemoradiation therapy against aggressive, drug-resistant head and neck tumors.
Credit: D. Lapotko/Rice University
Usage Restrictions: Must credit: D. Lapotko/Rice University
Related news release: 'Quadrapeutics' works in preclinical study of hard-to-treat tumors